SFXN1 and neoplasm: The results proved that upregulated SFXN1 expression was significantly associated with lower IC50 values for almost all clinical chemotherapy drugs and targeted therapies, except for erlotinib, indicating that patients with upregulated SFXN1 expression are presumably more receptive to anti-tumor drugs (Fig. 7A, B).